Limited-sampling models for estimation of the carboplatin area under the curve

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4571-4575

  Miyazaki, Mitsuru ^a   Fujiwara, Yasuhiro ^a   Takahashi, Toshiaki ^a   Isobe, Takeshi ^a   Ohune, Terumasa ^b   Tsuya, Takafumi ^b   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b Kure Rosai General Hospital   (Japan)

Author keywords

Carboplatin; Limited sampling model; Lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MATHEMATICAL MODEL; MULTIPLE REGRESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 0031427014     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J: Pharmacokinetics and dose reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
2. Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, J Calvert AH: Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin: Eur J Cancer Clin Oncol 23: 1399-1405, 1987.
3. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528, 1992.
4. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, Sandberg E, Stroeyer I: Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group Study. J Clin Oncol 15: 193-198, 1997.
5. van Warmerdam LJC, ten Bokkel Huinink WW, Macs RAA, Beijen JH: Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120: 427-433, 1994.
6. Sorensen BT, Stomgren A, Jakobsen P, Jakobsen A: A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324-327, 1993.
7. van Warmerdam LJC, Rodenhuis S, van Tellingen O, Macs RAA, Beijnen JH: Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35: 179-181, 1994.
8. Ohune T, Fujiwara Y, Sumiyoshi H, Yamaoka N, Yamakido M: Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer. Jpn J Cancer Res 86: 490-500, 1995.
9. LeRoy AF, Wehling ML, Sposeller HL, Friauf WS, Solomon RE, Dedrick RL: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184-191, 1977.
10. D'Argenio and Scumitzky A: A program package for simulation and parameter estimation in pharmacokinetic system. Comput Prog Biomed 9: 115-134, 1979.
11. Sheiner LB and Beal SL: Scientific commentary. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512, 1981.
12. Aswad SG, Calvert AH, Newell DR: A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37: 429-434, 1996.
13. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 45: 6502-6506, 1985.
14. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Alilshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
15. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573-580, 1995.
16. Fujiwara Y, Takahashi T, Ohune T, Tsuya T, Yamakido M, Egorin MJ: Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 89: 260-261, 1997.
17. van Warmerdam LJC, Rodenhuis S, vander Wall E, Macs RAA, Beijnen JH: Pharmacokinetics and Pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 73: 979-984, 1996.
18. Chatelut E, Chevreau C, Canal P: Response; Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 89: 261-262, 1997.